Anika Therapeutics (ANIK) CG 2025 Musculoskeletal Conference summary

Strategic direction and market positioning

• Recently completed a strategic refresh, focusing on value-building opportunities over the next few years.

• Holds the number one market share in U.S. osteoarthritis pain management and is emerging as a leader in regenerative orthopedic solutions.

• Current U.S. addressable market is $1 billion, with pipeline products expected to add $2 billion more.

• Strong financial position with no debt and ongoing share buyback; no need for fundraising.

• Revenue mix is shifting toward high-growth commercial channels, projected to be half of total revenue by 2026.

Product portfolio and innovation

• Orthovisc and Monovisc are leading viscosupplement products in the U.S., sold through a major partner, with strong double-digit growth internationally.

• Integrity Implant System, a regenerative tendon repair product, is growing 40% sequentially and is expanding into new anatomical applications.

• Hyalofast, a single-stage cartilage repair product, is expected to launch in the U.S. by 2026, adding a $1 billion market opportunity.

• Cingal, a next-generation osteoarthritis pain product, is in advanced FDA discussions and already leads in over 40 countries outside the U.S.

• All products leverage proprietary hyaluronic acid technology, with ongoing development of new regenerative solutions.

Competitive differentiation and clinical data

• Integrity outperforms market-leading collagen products in regenerative capacity and strength, with strong surgeon adoption due to ease of use and robust instrumentation.

• Hyalofast offers a single-stage, off-the-shelf solution versus competitors requiring two surgeries, with a lower anticipated price point and broad clinical indications.

• Cingal delivers over 70% pain reduction for at least six months, with a 90%+ responder rate across three phase III trials, and is non-opioid and non-addictive.

• No cannibalization observed between Cingal and other products; Cingal is used where steroids would otherwise be chosen.

• Integrity’s growth is driven by superior regenerative properties, strength, and tailored instrumentation, with further product line expansion planned.